The Beck Depression Inventory (BDI) is a 21-item self reporting questionnaire for evaluating the severity of depression in normal and psychiatric populations [1,2]. Developed by Beck et al in 1961, it relied on the theory of negative cognitive distortions as central to depression [3]. It underwent major revisions in 1978; the BDI-IA and 1996; the BDI-II, both copyrighted [4]. The BDI-II does not rely on any particular theory of depression and the questionnaire has been translated into several languages. A shorter version of the questionnaire; the BDI Fast Screen for Medical Patients (BDI-FS) is available for primary care use. That version
Background: Burnout is a pervasive health condition affecting many doctors at various stages in their careers. Characterised by emotional exhaustion, depersonalisation, and a reduced sense of personal accomplishment it can result in significant personal and professional consequences putting patient care at risk. Emotion regulation describes a capacity to self-modulate emotions to achieve desirable emotional outcomes. Emotional intelligence theory suggests that emotion regulation skills facilitate the maintenance of appropriate emotions, reducing or adapting undesirable emotions in oneself and others. Emotion regulation is usually automatic but can be controlled through learnt strategies. There is evidence that occupationally stressed individuals are less capable of down-regulating negative emotions. This paper systematically reviews studies of the role of emotion regulation in burnout in doctors. Aims: To examine the relationship between emotion regulation and burnout among doctors.
O ur survey aimed to determine whether educational deficits exist regarding patients' knowledge of current driving regulations. We surveyed 100 insulintreated diabetes patients using questionnaires in October 2008. Fifty-eight were male and 42 female. Mean age was 52.9 years, mean duration of diabetes 15.1 years and mean glycated haemoglobin A 1C 7.5%. Eighty-nine patients (89%) had notified the UK Driver and Vehicle Licensing Agency and 79 (79%) their insurance company of insulin treatment. Sixty-five patients (65%) said they would consider checking their capillary blood glucose levels before each driving episode. The mean length of time patients said they would consider rechecking their capillary blood glucose levels during long journeys was 2.8 hours and the median time they will consider waiting before resuming driving after a hypoglycaemic episode was 45 minutes. The mean capillary blood glucose level that patients said they would consider safe to drive with was 4.8 mmol/L. Thirty-five patients (35%) said they were unaware that driving was not permitted for at least 45 minutes after hypoglycaemia had resolved. We concluded that there were deficits in aspects of patients' knowledge of current driving regulations. Br J Diabetes Vasc Dis 2010;10:31-34
The treatment of patients diagnosed with a coexisting psychiatric and psychoactive substance misuse disorder remains an important clinical challenge in mental health nursing. This is not only because of the complexity of the disorder, but also because an increasing number of patients are presenting both disorders (i.e. coexisting psychiatric and psychoactive substance disorder). This article will review the literature on the subject of severe mental illness and substance misuse by examining various issues, including the phenomenon of dual diagnosis and its prevalence, the nature of the relationship between substance misuse and severe mental illness, the extent of the problem of illicit substance use among the psychiatric population, treatment trends and management models.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.